OTs' Role in Screening and Addressing Polypharmacy Side Effects With Geriatric Clients

2021 ◽  
Vol 75 (Supplement_2) ◽  
pp. 7512510234p1-7512510234p1
Author(s):  
Anna M. Quigg ◽  
Ashley Marks ◽  
Jamison Hogan ◽  
Brett Campbell ◽  
Dustin Cox
Keyword(s):  
United States ◽  
Older Adults ◽  
Side Effects ◽  
High Risk ◽  
Cost Effective ◽  
The United States ◽  
Willingness To Intervene ◽  
Primary Author

Abstract Date Presented 04/200/21 Older adults in the United States are at high risk for polypharmacy, which is related to increased falls, confusion, constipation, weakness, and tiredness. OTs are uniquely prepared to notice function-related impairments due to polypharmacy but do not routinely screen for or address it. This study found that an infographic increased OTs' knowledge of and willingness to intervene regarding polypharmacy and may be cost effective and time efficient in encouraging OTs to attend to polypharmacy side effects. Primary Author and Speaker: Anna M. Quigg Contributing Authors: Jennifer Gordon, Allison Bigg, Kathleen Graser, and Victoria Fichter

Syndrome of Inappropriate Antidiuretic Hormone Associated with Escitalopram Therapy

CNS Spectrums ◽  
2006 ◽  
Vol 11 (6) ◽  
pp. 429-432 ◽  
Author(s):  
Anjali Nirmalani ◽  
Saundra L. Stock ◽  
Glenn Catalano
Keyword(s):  
United States ◽  
Side Effects ◽  
High Risk ◽  
Antidiuretic Hormone ◽  
Side Effect ◽  
Parent Compound ◽  
The United States ◽  
Side Effect Profile ◽  
Significant Side Effect ◽  
Risk Patients

ABSTRACTEscitalopram is the selective serotonin reuptake inhibitor (SSRI) most recently approved for use in the United States. It is structurally related to citalopram, but is felt to have a more tolerable side-effect profile than its parent compound. Side effects are not generally serious and include headache, diarrhea, and nausea. While hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) have been associated with treatment with other SSRIs, there has only been one case of escitalopram-induced SIADH reported in the literature to date. We now report another case of a patient who developed SIADH after being treated with escitalopram for 4 weeks. The patient's hyponatremia improved following the discontinuation of escitalopram. Clinicians should be aware of this uncommon but significant side effect of SSRIs and monitor high-risk patients for the development of SIADH.

scholarly journals Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States

2021 ◽  
Author(s):  
Rui Li ◽  
Hanting Liu ◽  
Christopher Kit Fairley ◽  
Zhuoru Zou ◽  
Li Xie ◽  
...  
Keyword(s):  
United States ◽  
Older Adults ◽  
Cost Effectiveness ◽  
Booster Vaccination ◽  
Cost Effective ◽  
The United States ◽  
Cost Ratio ◽  
System Perspective ◽  
Benefit Cost Ratio ◽  
The Cost

Background: Over 86% of older adults aged ≥65 years are fully vaccinated against SARS-COV-2 in the United States (US). Waning protection of the existing vaccines promotes the new vaccination strategies, such as providing a booster shot for those fully vaccinated. Methods: We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy of Pfizer-BioNTech BNT162b2 (administered 6 months after 2nd dose) in those aged ≥65 years, from a healthcare system perspective. Findings: Compared with 2-doses of BNT162b2 without a booster, the booster strategy in a 100,000 cohort of older adults would incur an additional cost of $3.4 million, but save $6.7 million in direct medical costs in 180 days. This corresponds to a benefit-cost ratio of 1.95 and a net monetary benefit of $3.4 million. Probabilistic sensitivity analysis indicates that with a COVID-19 incidence of 9.1/100,000 person-day, a booster strategy has a high chance (67%) of being cost-effective. The cost-effectiveness of the booster strategy is highly sensitive to the population incidence of COVID-19, with a cost-effectiveness threshold of 8.1/100,000 person-day. This threshold will increase with a decrease in vaccine and booster efficacies. Doubling the vaccination cost or halving the medical cost for COVID-19 treatment alone would not alter the conclusion of cost-effectiveness, but certain combinations of the two might render the booster strategy not cost-effective. Interpretation: Offering BNT162b2 boosters to older adults aged ≥65 years in the US is likely to be cost-effective. Less efficacious vaccines and boosters may still be cost-effective in settings of high SARS-COV-2 transmission. Funding: National Natural Science Foundation of China. Berlina and Bill Gates Foundation

Weight Identity Among Older Adults in the United States: Genetic and Environmental Influences

2018 ◽  
pp. 262-274
Author(s):  
Robbee Wedow ◽  
Daniel A. Briley ◽  
Susan E. Short ◽  
Jason Boardman
Keyword(s):  
United States ◽  
Older Adults ◽  
Social Identity ◽  
Weight Status ◽  
Environmental Influences ◽  
Subjective Assessment ◽  
The United States ◽  
Men And Women ◽  
Perceived Weight ◽  
Midlife Adults

This chapter uses twin pairs from the Midlife in the United States study to investigate the genetic and environmental influences on perceived weight status for midlife adults. The inquiry builds on previous work investigating the same phenomenon in adolescents, and it shows that perceived weight status is not only heritable, but also heritable beyond objective weight. Subjective assessment of physical weight is independent of one’s physical weight and described as “weight identity.” Importantly, significant differences are shown in the heritability of weight identity among men and women. The chapter ends by discussing the potential relevance of these findings for broader social identity research.

Sign in / Sign up

Export Citation Format

Share Document